decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
National_Coverage_Determinations_Manual / Photosensitive_drugs
Subscribe or sign in to view the full article.
Article Overview
This page is a short National Coverage Determinations Manual section on photosensitive drugs used in photodynamic therapy. It explains the general role of this drug class, highlights verteporfin as the principal example, and references the Medicare coverage framework for ocular photodynamic therapy, including related diagnosis and diagnostic test references. The content is most relevant to coders, billing staff, and clinicians working with ophthalmology-related Medicare policy.
Why This Topic Matters
It helps readers identify that the article is policy-focused rather than a clinical treatment guide, and that it centers on a specific photosensitive drug and Medicare coverage context. This is useful for anyone checking whether the full manual section applies to an ophthalmology claim or documentation scenario.
What You Will Learn
- How the manual defines photosensitive drugs in the context of photodynamic therapy
- Which drug is highlighted as the primary covered example in the section
- How the article situates the topic within Medicare coverage policy for ocular photodynamic therapy
- What types of supporting diagnostic references are mentioned in relation to the coverage discussion
Who Should Read This
- Medical coders
- Billing specialists
- Compliance staff
- Ophthalmology practice staff
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com